Experimental Physiology
	

Celebrating 100 years
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Physiology in Press

First published online on January 14, 2005.
Experimental Physiology (2005)
DOI: 10.1113/expphysiol.2004.028464
© The Physiological Society 2005

A more recent version of this article appeared on May 1, 2005
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
90/3/291    most recent
expphysiol.2004.028464v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chao, J.
Right arrow Articles by Chao, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chao, J.
Right arrow Articles by Chao, L.

Received October 22, 2004
Revised December 1, 2004
Accepted after revision December 14, 2004


Cardiovascular control

Kallikrein/Kinin in Stroke, Cardiovascular and Renal Disease

Julie Chao 1* Lee Chao 1

1 Medical University of South Carolina

* To whom correspondence should be addressed. E-mail: chaoj{at}musc.edu.


   Abstract
SUMMARY Tissue kallikrein, a serine proteinase, produces the potent vasodilator kinin peptide from kininogen substrate. The levels of tissue kallikrein are reduced in humans and animal models with hypertension, cardiovascular and renal disease. Using transgenic and somatic gene transfer approaches, we investigated the role of the tissue kallikrein-kinin system in cardiovascular, renal and central nervous systems. A single injection of the human tissue kallikrein gene in plasmid DNA or an adenoviral vector resulted in a prolonged reduction of blood pressure and attenuation of hypertrophy and fibrosis in the heart and kidney of several hypertensive animal models. Furthermore, enhanced kallikrein/kinin levels after gene transfer exerted beneficial effects in protection against cardiac remodeling, renal injuries, restenosis, cerebral infarction and neurological deficits in normotensive animal models without hemodynamic effects, indicating direct actions of kallikrein independent of its ability to lower blood pressure. These kallikrein's effects were mediated by the kinin B2 receptor, as icatibant abolished the actions of kallikrein. Moreover, kallikrein/kinin had pleiotropic effects in inhibiting apoptosis, inflammation, hypertrophy and fibrosis, and promoting angiogenesis and neurogenesis in the heart, kidney, brain and blood vessel. Exogenous administration of kallikrein also led to increased nitric oxide (NO)/cGMP and cAMP levels, and reduced NAD(P)H oxidase activation and inflammatory cytokine levels. These results indicate a novel role of kallikrein/kinin through the kinin B2 receptor as an anti-oxidant and anti-inflammatory agent in protection against stroke, cardiovascular and renal disease, and may uncover new drug targets for the prevention and treatment of heart failure, vascular injury, end-stage renal disease and stroke in humans. Key words: tissue kallikrein, kinin, gene therapy, protein infusion, hypertension, oxidative stress, inflammation, heart, kidney, blood vessel, brain

Key Words: Bradykinin, Hypertension, Inflammation







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the The Physiological Society.